New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs

被引:5
作者
Pinto, Soraia Filipa Tavares [1 ,2 ]
Santos, Helder Almeida [3 ,4 ,5 ]
Sarmento, Bruno Filipe Carmelino Cardoso [1 ,6 ,7 ]
机构
[1] Univ Porto, Inst Invest & Inovacao Saude I3S, Porto, Portugal
[2] Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS, Porto, Portugal
[3] Univ Helsinki, Fac Pharm, Drug Res Program, Div Pharmaceut Chem & Technol, Helsinki, Finland
[4] Univ Groningen, Univ Med Ctr Groningen, WJ Kolff Inst Biomed Engn & Mat Sci, Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Biomed Engn, Groningen, Netherlands
[6] CESPU, IUCS, Gandra, Portugal
[7] Univ Porto, Inst Invest & Inovacao Saude I3S, Rua Alfredo Allen 208, P-4200135 Porto, Portugal
关键词
antidiabetic peptides; glucagon-like peptide-1; nanocarriers; oral delivery; type 2 diabetes mellitus; GLP-1 RECEPTOR AGONIST; TYPE-2; DIABETES-MELLITUS; BETA-CELL FUNCTION; POLYMERIC NANOPARTICLES; DPP4; INHIBITOR; DRUG DELIVERY; DUAL GIP; EXENATIDE; GLUCOSE; SYSTEM;
D O I
10.1002/wnan.1952
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that arises when the body cannot respond fully to insulin, leading to impaired glucose tolerance. Currently, the treatment embraces non-pharmacological actions (e.g., diet and exercise) co-associated with the administration of antidiabetic drugs. Metformin is the first-line treatment for T2DM; nevertheless, alternative therapeutic strategies involving glucagon-like peptide-1 (GLP-1) analogs have been explored for managing the disease. GLP-1 analogs trigger insulin secretion and suppress glucagon release in a glucose-dependent manner thereby, reducing the risk of hyperglycemia. Additionally, GLP-1 analogs have an extended plasma half-life compared to the endogenous peptide due to their high resistance to degradation by dipeptidyl peptidase-4. However, GLP-1 analogs are mainly administered via subcutaneous route, which can be inconvenient for the patients. Even considering an oral delivery approach, GLP-1 analogs are exposed to the harsh conditions of the gastrointestinal tract (GIT) and the intestinal barriers (mucus and epithelium). Hereupon, there is an unmet need to develop non-invasive oral transmucosal drug delivery strategies, such as the incorporation of GLP-1 analogs into nanoplatforms, to overcome the GIT barriers. Nanotechnology has the potential to shield antidiabetic peptides against the acidic pH and enzymatic activity of the stomach. In addition, the nanoparticles can be coated and/or surface-conjugated with mucodiffusive polymers and target intestinal ligands to improve their transport through the intestinal mucus and epithelium. This review focuses on the main hurdles associated with the oral administration of GLP-1 and GLP-1 analogs, and the nanosystems developed to improve the oral bioavailability of the antidiabetic peptides. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology
引用
收藏
页数:26
相关论文
共 100 条
[51]   Electrostatic Interaction on Loading of Therapeutic Peptide GLP-1 into Porous Silicon Nanoparticles [J].
Kaasalainen, Martti ;
Rytkonen, Jussi ;
Makila, Ermei ;
Narvanen, Ale ;
Salonen, Jarno .
LANGMUIR, 2015, 31 (05) :1722-1729
[52]   A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus [J].
Kalra, Sanjay ;
Sahay, Rakesh .
DIABETES THERAPY, 2020, 11 (09) :1965-1982
[53]   Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis [J].
Karagiannis, Thomas ;
Avgerinos, Ioannis ;
Liakos, Aris ;
Del Prato, Stefano ;
Matthews, David R. ;
Tsapas, Apostolos ;
Bekiari, Eleni .
DIABETOLOGIA, 2022, 65 (08) :1251-1261
[54]  
Kiptoo P, 2016, WILEY SER DRUG DISC, P19
[55]   The Discovery and Development of Liraglutide and Semaglutide [J].
Knudsen, Lotte Bjerre ;
Lau, Jesper .
FRONTIERS IN ENDOCRINOLOGY, 2019, 10
[56]   Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes [J].
Kolterman, OG ;
Buse, JB ;
Fineman, MS ;
Gaines, E ;
Heintz, S ;
Bicsak, TA ;
Taylor, K ;
Kim, D ;
Aisporna, M ;
Wang, Y ;
Baron, AD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (07) :3082-3089
[57]   Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide [J].
Lau, Jesper ;
Bloch, Paw ;
Schaffer, Lauge ;
Pettersson, Ingrid ;
Spetzler, Jane ;
Kofoed, Jacob ;
Madsen, Kjeld ;
Knudsen, Lotte Bjerre ;
McGuire, James ;
Steensgaard, Dorte Bjerre ;
Strauss, Holger Martin ;
Gram, Dorte X. ;
Knudsen, Sanne Moller ;
Nielsen, Flemming Seier ;
Thygesen, Peter ;
Reedtz-Runge, Steffen ;
Kruse, Thomas .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (18) :7370-7380
[58]   The Glucose-Lowering Potential of Exenatide Delivered Orally via Goblet Cell- Targeting Nanoparticles [J].
Li, Xiang ;
Wang, Chenhui ;
Liang, Rongcai ;
Sun, Fengying ;
Shi, Yanan ;
Wang, Aiping ;
Liu, Wanhui ;
Sun, Kaoxiang ;
Li, Youxin .
PHARMACEUTICAL RESEARCH, 2015, 32 (03) :1017-1027
[59]   Orally administered intelligent self-ablating nanoparticles: a new approach to improve drug cellular uptake and intestinal absorption [J].
Liang, Yanzi ;
Ding, Ruihuan ;
Wang, Huihui ;
Liu, Lanze ;
He, Jibiao ;
Tao, Yuping ;
Zhao, Zhenyu ;
Zhang, Jie ;
Wang, Aiping ;
Sun, Kaoxiang ;
Li, Youxin ;
Shi, Yanan .
DRUG DELIVERY, 2022, 29 (01) :305-315
[60]  
Lily E., Prescribing information sheet of Trulicity® (dulaglutide)